Omadacycline Tosylate is an active aminomethylcycline antibiotic belonging to the Tetracycline class. It can be used to research acute bacterial skin and skin-structure infections, community-acquired pneumonia and urinary tract infections. The compound was approved by the US FDA in 2018. It was invented at Tufts University School of Medicine and developed by Paratek Pharmaceuticals (Boston, MA) with the aim of identifying novel minocycline derivatives at the C-9 position.
|Mechanism of Action||Similar to Tetracyclines, Omadacycline Tosylate binds to 30S ribosomal subnit in the mRNA translation complex and inhibits binding of aminoacyl-tRNA to the mRNA-riboxome complex, thus inhibiting protein synthesis. Omadacycline inhibits bacterial protein synthesis with a greater potecy than tetracycline. Biophysical studies with isolated ribosomes showed that the binding site for Omadacycline is similar to tetracycline, but unlike tetracycline, Omadacycline is active in vitro in the presence of ribosomal protection protein (Tet(O).|
Omadacycline Tosylate has broad-spectrum activity against Gram-positive and Gram-negative bacteria, anaerobic, and atypical bacteria. It has activity against Mycobacteria including rapidly growing mycobacteria (RGM). It has potent activity against methicillin-resistant Staphylococcus aureus (MRSA). Omadacycline is active against bacteria carrying the major efflux and target protection resistance determinants. This includes strains that are normally resistant to tetracyclines, but also strains that are resistant to quinolones, macrolides and aminoglycosides.
Additional in vitro and in vivo studies of omadacycline metabolism, disposition, and drug interactions show that omadacycline is metabolically stable (i.e., it does not undergo significant biotransformation) and neither inhibits nor interacts with metabolizing enzymes or transporters. Omadacycline has activity against bacterial strains expressing the two main forms of tetracycline resistance (efflux and ribosomal protection). It is capable of evading efflux and target protection antibacterial resistance mechanisms.
Omadacycline has activity against Nontuberculous mycobacteria (NTM) include Mycobacterium abscessus compex (MAC) and Mycobacterium avium complex is promising during in vitro MIC testing. Additional research focusing on tetracycine resistance mechanisms and dynamic models may be warranted (Brown-Elliott and Wallace, 2021).
Brown-Elliott BA and Wallace RJ Jr (2021) In vitro susceptibility testing of Omadacycline against nontuberculous Mycobacteria. Antimicrob. Agents Chemother.65(3):e01947-20 PMID 33288634
Bryant AE, Dennis L Stevens DL (2023) Investigating the immunomodulatory activities of omadacycline, J. Antimicrob. Chemother. 78 (1):78–83 PMID 36272138
Draper MP et al (2014) Mechanism of action of the novel aminomethylcycline antibiotic Omadacycline. Antimicrob. Agents Chemother. 58(3):1279-1283. PMID 24041885
Durães F and Sousa E (2019) Omadacycline: A newly approved antibacterial from the class of tetracyclines. Pharmaceuticals (Basel). 12(2):63 PMID 31010063
Macone AB et al (2014) In vitro and in vivo antibacterial activities of Omadacycline, a novel aminomethylcycline. Antimicrob. Agents Chemother. 58:1127-1135 PMID 24295985